Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.

By G. Zalcman, J. Mazières, J. Margery, L. Greillier, C. Audigier-Valette, D. Moro-Sibilot, O. Molinier, R. Corre, I. Monnet, V. Gounant and 11 more. The Lancet, 2016

857 citations recorded by the source corpus.

Subfields: Biotechnology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/8ee626922b72e7539c2df95f048211f0ffdc19c3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. L. Castelletti
2. J. Rasko
3. D. Yeo
4. N. van Zandwijk

Citations in the corpus

• Hitting the Bull’s-Eye: Mesothelin’s Role as a Biomarker and Therapeutic Target for Malignant Pleural Mesothelioma (2021, background): “This directional change is bearing fruit, as exemplified by a randomized (phase III) study, carried out by a French cooperative group, that observed prolonged survival rates as a consequence of the addition of the antiangiogenic drug bevacizumab to the pemetrexed/cisplatin combination [10] and the F”